Placing Settlement

RNS Number : 6586U

MGC Pharmaceuticals Limited

06 December 2021

 

MGC Pharmaceuticals Ltd.

Placing Settlement

6 December 2021

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (' MGC Pharma' or ' the Company '), a European based bio-pharma company specialising in the production and development of phytomedicines , advises that further to the Announcement made on 30 November 2021 notifying the market of the successful Bookbuild for its UK focused £5,500,000 Placing, settlement by Delivery versus Payment (DvP) is scheduled to occur tomorrow, Tuesday, 7 December 2021. Admission of the 275,000,000 Fully Paid Ordinary Shares, issued pursuant to the fundraise, to the standard segment of the Official List of the Financial Conduct Authority and to trading on the Main Market of the London Stock Exchange plc is expected to take place tomorrow, Tuesday, 7 December 2021, at 8.00am (London time). Quotation of these shares on the Australian Securities Exchange is also scheduled to take place tomorrow, Tuesday, 7 December 2021. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

Upon admission, the Company will have 2,698,569,008 Ordinary Shares of no par value on issue and there are no shares held in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

Authorised for release by the Chairman, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [phone] [e-mail]	UK PR Advisors - Tavistock Charles Vivian / Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

MSCUPGCPPUPGUBQ